MELBOURNE, Australia, Sept. 20 /PRNewswire-FirstCall/ -- Australian adult stem cell company, Mesoblast Limited, today announced positive initial results of clinical adult stem cell trials for the treatment of heart disease being conducted in conjunction with its United States-based sister company Angioblast Systems Inc.
